Chronic pulmonary sepsis is the predominant cause of morbidity for patients with cystic fibrosis (CF) and non-CF bronchiectasis. Previously it was thought that respiratory infection in these patients was mostly limited to a very small number of typical pathogens; however, in recent years there have been increasing reports of infection with other emerging potential pathogens including Burkholderia, Stenotrophomonas, Achromobacter, Ralstonia, Pandoraea, nontuberculous mycobacteria, and fungal species. Furthermore, culture-independent methodologies have established that the lungs of patients with CF and non-CF bronchiectasis comprise mixed microbiological communities of aerobic and anaerobic bacteria, fungal and viral species, collectively referred to as the lung microbiome. This article addresses the clinical relevance of emerging pathogens and the lung microbiome in CF and non-CF bronchiectasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-0035-1546752 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reconsidering the Diagnosis: Abnormal Sweat Chloride Tests in Non-CF Bronchiectasis.
Pediatr Pulmonol
January 2025
Department of Internal Medicine, Division of Pulmonary and Critical Care, University of Virginia, Charlottesville, Virginia, USA.
Introduction: While the diagnosis of cystic fibrosis (CF) is often straightforward and reliant on correlation between genetic testing and clinical signs and symptoms, there is a subset where the distinction is not nearly as clearcut. This has previously been reported in patients identified through newborn screening but not meeting full CF diagnostic criteria, earning the label of CF Screen Positive, Inconclusive Diagnosis (CFSPID) instead. A homologous diagnostic category in adults is named CF Transmembrane Conductance Regulator-Related Disorder (CFTR-RD).
View Article and Find Full Text PDFDisarming the cavalry: targeting neutrophils to limit collateral damage in non-CF bronchiectasis.
Eur Respir J
January 2025
Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Lung function trajectories in children with early diagnosis of non-cystic fibrosis bronchiectasis: a retrospective observational study.
Ital J Pediatr
November 2024
Department of Pediatrics, Buzzi Children's Hospital, Milan, Italy.
Background: Non-cystic fibrosis (non-CF) bronchiectasis (BE) is defined as a clinical syndrome of recurrent, persistent wet cough and abnormal bronchial dilatation on chest High Resolution Computed Tomography (HRCT) scans. The aims of this study were to characterize the pattern of the trajectories of lung function parameters and to consider the relationship between the lung function and radiological severity according to the modified Reiff score.
Methods: The study retrospectively considered 86 children (46.
Protein phosphatase 2A activators under investigation for smoking-related chronic obstructive pulmonary disease and related disorders.
Expert Opin Investig Drugs
November 2024
Faculty of Medicine, 3rd Department, University of Medicine and Pharmacy, Carol Davila Bucuresti, Bucuresti, Romania.
Article Synopsis
- Chronic obstructive pulmonary disease (COPD) and other chronic respiratory disorders like cystic fibrosis and alpha-one antitrypsin deficiency share inflammation and progression characteristics, prompting investigations into anti-inflammatory treatments.
- A systematic review of studies from 2000 onward focuses on the role of protein phosphatase 2A (PP2A) in inflammation, its suppression by smoking, and the potential benefits of its activation in treating COPD.
- Experts suggest that activating PP2A could be a viable therapy for COPD and related disorders, highlighting promising avenues like repurposing metformin and inhalation methods, although most evidence is still in the experimental stage.
Article Synopsis
- - Chronic airway inflammation is a major factor in bronchiectasis, influenced by neutrophils that release harmful proteins called neutrophil serine proteases (NSPs) in both cystic fibrosis (CF) and non-CF conditions.
- - There’s an imbalance between NSPs and their counteracting proteins in patients with CF and non-CF bronchiectasis, but effective treatments targeting NSPs are currently lacking.
- - Even with new CFTR modulator therapies improving outcomes for cystic fibrosis patients, airway inflammation remains a problem, highlighting the need for new treatment strategies focused on managing neutrophilic inflammation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!